Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of Spravato in treatment-resistant bipolar depression
NL-OMON59811Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esketamine in bipolar disorder (BD), sponsored by Leiden University Medical Center. Primary endpoints: MADRS response rate and MADRS remission rate. Started Apr 2025; status: recruiting.
02
Drugs
esketamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NL-OMON59811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59811.